{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:13:51Z","timestamp":1788984831576,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01852-5","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:16:45Z","timestamp":1785431805000},"page":"4585-4598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"16","author":[{"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis P.","family":"Sanden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Chicharro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Serra-Baldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahreen","family":"Ameen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Fakhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-0908","authenticated-orcid":false,"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"4s","key":"1852_CR1","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","volume":"139","author":"T Bieber","year":"2017","unstructured":"Bieber T, D\u2019Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Sch\u00e4ppi G, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol. 2017;139(4s):S58-s64.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1852_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/21556660.2019.1619570","volume":"8","author":"E Kowalska-Ol\u0119dzka","year":"2019","unstructured":"Kowalska-Ol\u0119dzka E, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126\u20138.","journal-title":"J Drug Assess"},{"issue":"9","key":"1852_CR3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1852_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1852_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2019.03.037","volume":"81","author":"L Eckert","year":"2019","unstructured":"Eckert L, Gupta S, Gadkari A, Mahajan P, Gelfand JM. Burden of illness in adults with atopic dermatitis: analysis of National Health and wellness survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019;81(1):187\u201395.","journal-title":"J Am Acad Dermatol"},{"key":"1852_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061298","author":"M Talamonti","year":"2021","unstructured":"Talamonti M, Galluzzo M, Silvaggio D, Lombardo P, Tartaglia C, Bianchi L. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10061298.","journal-title":"J Clin Med"},{"issue":"1","key":"1852_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/jdv.15919","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Langenbruch A, Blome C, Gutknecht M, Werfel T, St\u00e4nder S, et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1852_CR8","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174-90.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1852_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/pde.14971","volume":"39","author":"HA Ram\u00edrez-Mar\u00edn","year":"2022","unstructured":"Ram\u00edrez-Mar\u00edn HA, Silverberg JI. Differences between pediatric and adult atopic dermatitis. Pediatr Dermatol. 2022;39(3):345\u201353.","journal-title":"Pediatr Dermatol"},{"key":"1852_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20639","author":"A Wollenberg","year":"2025","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, et al. European guideline (EuroGuiDerm) on atopic eczema: living update. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20639.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1852_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/all.12498","volume":"70","author":"T Bieber","year":"2015","unstructured":"Bieber T, Straeter B. Off-label prescriptions for atopic dermatitis in Europe. Allergy. 2015;70(1):6\u201311.","journal-title":"Allergy"},{"issue":"7","key":"1852_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/exd.13911","volume":"28","author":"M Moyle","year":"2019","unstructured":"Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756\u201368.","journal-title":"Exp Dermatol"},{"key":"1852_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03137-3","author":"M Augustin","year":"2025","unstructured":"Augustin M, Serra-Baldrich E, Seneschal J, Grond S, Lampropoulou A, Elrayes M, et al. Baseline characteristics and treatment patterns of patients with atopic dermatitis treated with oral systemic therapies: an interim analysis of the AD-REAL study. Adv Ther. 2025. https:\/\/doi.org\/10.1007\/s12325-025-03137-3.","journal-title":"Adv Ther"},{"key":"1852_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1386","author":"DMR Davis","year":"2025","unstructured":"Davis DMR, Frazer-Green L, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Focused update: guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1386.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1852_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/bjd\/ljae342","volume":"192","author":"C Haag","year":"2025","unstructured":"Haag C, Alexis A, Aoki V, et al. A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council. Br J Dermatol. 2025;192(1):135\u201343. https:\/\/doi.org\/10.1093\/bjd\/ljae342.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1852_CR16","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1080\/09546634.2022.2038361","volume":"33","author":"M de Bruin-Weller","year":"2022","unstructured":"de Bruin-Weller M, Pink AE, Ferrucci SM, Patrizi A, Svensson A, Schuttelaar MLA, et al. Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD). J Dermatolog Treat. 2022;33(5):2565\u201370.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1852_CR17","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/bjd\/ljae287","volume":"191","author":"H Alexander","year":"2024","unstructured":"Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, et al. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK\u2013Irish A-STAR register. Br J Dermatol. 2024;191(6):988\u201399.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1852_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s13555-022-00882-z","volume":"13","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Cortese A, Avagliano J, Valenti M, Costanzo A, et al. Real-life effectiveness and safety of Upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: a single-center 16-week study. Dermatol Ther (Heidelb). 2023;13(2):651\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1852_CR19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"24","key":"1852_CR20","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"6","key":"1852_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","volume":"157","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol. 2021;157(6):691\u20139.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1852_CR22","first-page":"1","volume":"157","author":"A Costanzo","year":"2022","unstructured":"Costanzo A, Amerio P, Asero R, Chiricozzi A, Corazza M, Cristaudo A, et al. Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Ital J Dermatol Venerol. 2022;157(1):1\u201312.","journal-title":"Ital J Dermatol Venerol"},{"key":"1852_CR23","doi-asserted-by":"publisher","first-page":"adv14153","DOI":"10.2340\/actadv.v103.14153","volume":"103","author":"Z Reguiai","year":"2023","unstructured":"Reguiai Z, Becherel PA, Perrot JL, Fougerousse AC, Begon E, Poreaux C, et al. Impact of baricitinib on patients\u2019 quality of life after one year of treatment for atopic dermatitis in real-world practice: results of the observatory of chronic inflammatory skin diseases registry. Acta Derm Venereol. 2023;103:adv14153.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1852_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaad.2017.08.002","volume":"78","author":"L Eckert","year":"2013","unstructured":"Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol. 2013;78(1):54-61.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1852_CR25","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","volume":"154","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903\u201312.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1852_CR26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.36849\/JDD.2020.5422","volume":"19","author":"PA Lio","year":"2020","unstructured":"Lio PA, Wollenberg A, Thyssen JP, Pierce EJ, Rueda MJ, DeLozier AM, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19(10):943\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"1852_CR27","doi-asserted-by":"publisher","first-page":"adv00588","DOI":"10.2340\/00015555-3913","volume":"101","author":"A Soria","year":"2021","unstructured":"Soria A, Th\u00e9ni\u00e9 C, Bienenfeld C, Staumont-Sall\u00e9 D. General burden of adult atopic dermatitis: an observational study of disease perceptions among patients and dermatologists in France. Acta Derm Venereol. 2021;101(11):adv00588.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1852_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/1346-8138.14787","volume":"46","author":"N Katoh","year":"2019","unstructured":"Katoh N, Saeki H, Kataoka Y, Etoh T, Teramukai S, Takagi H, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): baseline characteristics, treatment history and disease burden. J Dermatol. 2019;46(4):290\u2013300.","journal-title":"J Dermatol"},{"key":"1852_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.644760","volume":"8","author":"FJ Legat","year":"2021","unstructured":"Legat FJ. Itch in atopic dermatitis\u2014What is new? Front Med (Lausanne). 2021;8:644760.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"1852_CR30","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s13555-024-01171-7","volume":"14","author":"JM Carrascosa","year":"2024","unstructured":"Carrascosa JM, Narcisi A, Nomura T, St\u00e4nder S, Vestergaard C, Sabatino S, et al. Baricitinib improvement across regions in atopic dermatitis patients with baseline body surface area up to 40% and severe itch. Dermatol Ther. 2024;14(6):1561\u201373.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1852_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1852_CR32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/jdv.19669","volume":"38","author":"A Wollenberg","year":"2024","unstructured":"Wollenberg A, Simon D, Kulthanan K, Figueras-Nart I, Misery L, Tangsirisap N, et al. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema area and severity index (EASI) clinical subscores. J Eur Acad Dermatol Venereol. 2024;38(4):695\u2013702.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1852_CR33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s13555-024-01330-w","volume":"15","author":"M Augustin","year":"2025","unstructured":"Augustin M, Napolitano M, Izu-Belloso R, Kleyn CE, Silvia S, Grond S, et al. Baricitinib provides significant improvements in quality of life and functioning in adults with moderate-to-severe atopic dermatitis with baseline body surface area \u2264 40% and severe itch. Dermatol Ther (Heidelb). 2025;15(2):437\u201344.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1852_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01852-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:16Z","timestamp":1788981676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01852-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1852"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01852-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Matthias Augustin served as a consultant or paid speaker for clinical trials sponsored by companies including AbbVie, Almirall, Eli Lilly and Company, Pfizer and received support for attending meetings\/travel from Eli Lilly and Company. Andreas Pinter has received payment or honoraria from Eli Lilly and Company and has participated on a data safety board or advisory board from Eli Lilly and Company. Inmaculada De La Torre, Silvia Sabatino, and Louis P. Sanden are employees and minor shareholders in Eli Lilly and Company. Walid Fakhouri is an ex-employee and former minor shareholder in Eli Lilly and Company. Pablo Chicharro reports no conflicts of interest. Mahreen Ameen has acted as a consultant and\/or scientific advisor and\/or speaker and\/or principal investigator of clinical trials with Regeneron, Sanofi Genzyme, LEO-Pharma, Pfizer, AbbVie, Eli Lilly and Company, Galderma, and Almirall. Anthony Bewley reports receiving royalties from Practical Psychodermatology (Wiley 2014); ad hoc consultancy fees from AbbVie, Almirall, BMS, Eli Lilly and Company, Galderma, Incyte, LEO-Pharma, Janssen, Novartis, Pfizer, Sanofi, UCB; ad hoc lecturing fees from AbbVie, Almirall, BMS, Eli Lilly and Company, Galderma, Incyte, LEO-Pharma, Janssen, Novartis, Pfizer, Sanofi, UCB; support from attending BAB\/EADV\/ADD from Novartis, Galderma, UCB, Janssen, Sanofi; acted as an immediate past president of ESDaP and on the medical advisory board from the National Eczema Society, Ichthyosis Support Group, Psoriasis Association. Esther Serra-Baldrich reported receiving payment\/honoraria from LEO-Pharma, Sanofi, Galderma, Eli Lilly and Company, Pfizer, Almirall, and AbbVie; support for attending meetings\/travel from LEO-Pharma, Sanofi, Galderma, Eli Lilly and Company, Pfizer, Almirall, AbbVie; participated on a data safety monitoring board or advisory board for Sanofi, LEO-Pharma, Galderma, Pfizer, AbbVie, and Eli Lilly and Company. Julien Seneschal reports receiving grants from Sanofi; consulting fees from AbbVie, Almirall, Eli Lilly and Company, Pfizer, Sanofi, and L\u2019Oreal; honoraria from AbbVie, Almirall, Eli Lilly and Company, Pfizer, L\u2019Oreal, and Sanofi.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Pharmacoepidemiology Practices and applicable laws and regulations of the country or countries where the study is being conducted, as appropriate. The study protocol was approved by the Institutional Review Board or Ethics Committee at each participating site which included Le comit\u00e9 de protection des personnes \u00cele-de-France II (N\/A), Ethic Kommission der Arztekammer Hamburg (#2021-10562-BO-ff), Hospital Cl\u00ednico San Carlos (#22\/124-O_M_SP), and North of Scotland Research Ethics Committee (#21\/NS\/0085), and HRA and Health and Care Research Wales (#21\/NS\/0085). Written informed consent was obtained from all eligible participants before undergoing study-related procedures.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}